期刊名称：SCIENCE TRANSLATIONAL MEDICINE
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Mission: To promote human health by providing a forum for communication and cross-fertilization among basic, translational, and clinical research practitioners and trainees from all relevant established and emerging disciplines.
"Never before have scientists had access to the remarkable tools that are available today and that allow rigorous translational investigations to be conducted. However, the creation of a redefined discipline of translational medicine will require the emergence of a new and vibrant community of dedicated scientists, collaborating to fill knowledge gaps and dissolve or circumvent barriers to improved clinical medicine." ~Elias A. Zerhouni, M.D., Chief Scientific Advisor, Science Translational Medicine
A profound transition is required for the science of translational medicine. Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the rapid transformation of this knowledge into effective health measures continues to elude biomedical scientists. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human disease. Studies in humans often highlight deep gaps in our fundamental understanding of biology, but the linkages back to basic research to fill these gaps have not been as effective as they could be. Clearly, creative experimental approaches, novel technologies and new ways of conducting scientific explorations at the interface of established and emerging disciplines are now required to an unprecedented degree if real progress is to be made. Nothing short of a true reinvention of the science of translational medicine is likely to suffice. To aid in this reinvention, Science and AAAS have created a new interdisciplinary journal, Science Translational Medicine.
Audience: Researchers and management in academia, government, and the biotechnology and pharmaceutical industries; physician scientists; regulators; policy makers; investors; business developers; and funding agencies.
Scope: Cancer, cardiovascular disease, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, immunology/vaccines, infectious diseases, policy, behavior, bioengineering, physics, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine.
Content: The focus of Science Translational Medicine is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold Science Translational Medicine articles to the same high-quality standard that is the hallmark of the journal Science.
Examples of content in Science Translational Medicine:
Research and commentary on models of human disease with significant implications for disease treatment
Investigative studies of human biology with an emphasis on disease, including small clinical trials
Perspectives and Reviews on research topics that discuss the implications of the findings from a basic science and a clinical point of view
Survey of recent significant findings from other publications (Editor's Choice)
Commentary on policy, funding, and regulatory issues
Special issues that feature comprehensive reviews and analyses of current topics in translational medicine
Issue Elements: Approximately 1,500 print pages per year, 12-16 original peer-reviewed full-length research papers per month/three to four per week
Personalization: Science Translational Medicine provides customization features to tailor the site to the user's needs and interests (these features require registration and access through an institutional site license). Science Translational Medicine offers eTOC alerts, which alert users when a new issue of Science Translational Medicine is published, as well as three types of CiteTrack research alerts: (i) keyword alerts, (ii) author alerts, and (iii) citation alerts.
Users also can organize Science Translational Medicine content in Folders; select display settings that provide filters for searches; and save personalized searches to execute on demand.
Instructions to Authors
About Science Translational Medicine
Science Translational Medicine is a weekly journal devoted to issues and research of strong interest to the translational medicine community. Translational medicine topics suitable for submission include any original research findings, discussions or analyses that move the field closer to the goal of improving human health, or the diagnosis and treatment of disease. Interdisciplinary approaches are particularly encouraged, for example, studies at the interface of engineering and diagnostics, chemistry and drug development, or cell biology and clinical medicine. We accept original research as well as Reviews, Perspectives and Commentaries.
A major goal of the journal is to publish papers that identify and fill scientific knowledge gaps at the junction of basic research and human applications. In this vein, original research published in STM should report significant progress toward the prevention, diagnosis, or treatment of disease; serve as templates for future explorations and investments in the field of translational medicine; transform our understanding of human biology; be exceptionally innovative in its conceptual approach to a given problem; or catalyze new directions of explorations toward improved human health. These papers preferably will provide insights and evidence with influence beyond their own fields of research. Finally, we will publish papers that meet rigorous criteria of excellence and innovation, while providing authors with prompt and expert editing and peer review.
Back to Top
Categories of Manuscripts
Research Articles are original research papers that represent significant advances in translational medicine research. They should include an abstract and be structured as follows: Abstract, Introduction, Results, Discussion, Materials and Methods, References, Figures and Tables, Supplementary Material. Research articles should be 5000-7000 words in length with 5-7 figures and tables. Supplementary material is permitted in various formats but should be limited to information that is not essential to the general understanding of the research presented in the paper. View detailed instructions for Research Articles.
Perspectives are shorter pieces (1000-2000 words) that discuss the implications of recent research findings from both a basic and clinical point of view. They may focus on recently or concurrently published papers in Science Translational Medicine or other journals, or a cluster of recent developments. Perspectives are generally solicited by the editors but suggestions for topics and authors are welcome. View detailed instructions for Perspectives.
Commentaries (1000-3000 words) present overviews or analyses of current issues of interest to the translational medicine community. They can discuss regulatory, policy, legislative, funding or economic topics. Commentaries are generally solicited by the editors but suggestions for topics and authors are welcome. View detailed instructions for Commentaries.
Reviews (4000-8000 words) should provide a balanced overview of current knowledge about a disease or health condition or be a new synthesis of an active area of translational research (State-of-the-Field). Reviews of a disease should clearly identify bottlenecks in the translational system that are preventing progress in combating the disease. Or, Reviews may outline and present a methodology or technique of current interest in translational medicine (State-of-the-Art). Ideally Reviews should be comprehensive (but not specialized), interdisciplinary and provocative. Reviews are evaluated by peer review for scholarship, accuracy, clarity, and effectiveness of presentation. Reviews are generally solicited by the editors but suggestions for topics and authors are welcome. View detailed instructions for Reviews.
Back to Top
Editorial Policies
SUBMISSION REQUIREMENTS
Back to Top
Authorship
Authorship on a paper published in Science Translational Medicine requires that the individual has made one or more specific type of contribution to the research paper. Authors in Science Translational Medicine must fulfill the criteria laid out in the October 2005 update of the ISMJE (International Committee of Medical Journal Editors) definition of authorship. Specifically,
"Authorship credit should be based on (i) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (ii) drafting the article or revising it critically for important intellectual content; and (iii) final approval of the version to be published. Authors should meet conditions i, ii, and iii. All persons designated as authors should qualify for authorship, and all those who qualify should be listed."
Ghost authorship (in which individuals who have made author-level contributions to the paper are not included in the author list) is not permitted for papers published in Science Translational Medicine. Nor is guest or honorary authorship. Other individuals who have participated in generation of the research paper but who do not meet the criteria for authorship should be listed in the acknowledgement section with a brief indication of the nature of their contribution.
In addition, all authors must agree to be so listed and must have seen and approved the manuscript, its content, and its submission to Science Translational Medicine. Any changes in authorship must be approved in writing by all of the original authors. Science Translational Medicine will send an email to all authors to confirm receipt of each paper. Submission of a paper that has not been approved by all authors may result in immediate rejection without appeal.
Finally, in order to more explicitly detail the part that each author played in generating the published work, all authors must state his or her contribution to the study in the last numbered reference of the paper; this information will be published in the paper.
Back to Top
Prior Publication and Presentations at Meetings
Science Translational Medicine will not consider any original research paper or component of a research paper that has been published or is under consideration for publication elsewhere. Distribution on the Internet may be considered prior publication and may compromise the originality of the paper as a submission to Science Translational Medicine. Please contact the editors if you have questions regarding allowable postings.
We generally encourage presentation of original results prior to publication at scientific meetings. Nevertheless, press coverage and presentation at scientific conferences can sometimes affect consideration of papers at Science Translational Medicine. For example, reporting the main findings of a paper in the mass media can compromise the novelty of the work and thus its appropriateness for Science Translational Medicine. Therefore, authors should feel free to present their data at scientific meetings but should not overtly seek media attention or give copies of the figures or data from their manuscript to any reporter, unless the reporter agrees to abide by Science Translational Medicine's press embargo. If a reporter attends an author's session at a meeting and writes a story based only on the presentation, such coverage will not affect Science Translational Medicine's consideration of the author's paper. (For more information, please see the embargo entry in the Science Contributors FAQ.)
Back to Top
Human Subjects Research
Informed consent must be obtained for studies on humans after the nature and possible consequences of the studies are explained. A statement that informed consent was obtained must also appear in the manuscript. All research on humans must have approval from the institutional IRB (Institutional Review Board) or an equivalent body. The editors reserve the right to request IRB documents associated with a particular paper.
Back to Top
Animal Care
For all animal experimentation described in the manuscript, Science Translational Medicine requires that authors state in the Methods section their adherence to the NIH Guide for the Care and Use of Laboratory Animals, or the equivalent. For the full text of the NIH guidelines, see http://oacu.od.nih.gov/regs/guide/guide.pdf.
Back to Top
Registration of Clinical Trials
Science Translational Medicine requires, as a condition of consideration for publication, registration in a public trials registry. Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. We use the WHO definition of a clinical trial, that is, "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: Accessible to the public at no charge, searchable by standard electronic (Internet-based) methods, open to all prospective registrants free of charge or at minimal cost, validation of registered information, and identification of trials with a unique number. An acceptable registry also includes information on: the investigator(s), the research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing, or closed) and funding source(s).
Registries that currently meet these criteria include:
Any of the primary registers that participate in the WHO ICTRP (http://www.who.int/ictrp/en/)
The registry sponsored by the US National Library of Medicine (www.clinicaltrials.gov)
The International Standard Randomised Controlled Trial Number registry (www.controlled-trials.com)
The Cochrane Renal Group registry (http://www.cochrane-renal.org)
The National (UK) Research Register (https://portal.nihr.ac.uk/Pages/NRRArchive.aspx)
European Clinical Trials Database (http://eudract.emea.europa.eu/eudract/index.do)
Back to Top
Randomized Controlled Trials
Science Translational Medicine encourages authors who are submitting reports of randomized controlled trials to review the CONSORT Statement. The CONSORT Statement includes recommendations, a checklist of items that should be included in a comprehensive report, and a participant flow diagram. Reports of randomized controlled trials that do not conform to the CONSORT guidelines may be returned to authors for revision prior to formal review.
Back to Top
Unpublished Data and Personal Communications
Citations to unpublished data and personal communications cannot be used to support significant claims in the paper.
Back to Top
Related Papers
Copies of papers submitted to other journals or that are in press as of the date that the revised manuscript is returned by any of the authors that relate to the paper submitted to Science Translational Medicine must be included with the submission or revision. Access to this material will let the editors put the results in the submission in the proper context and make the best decision regarding your manuscript.
Back to Top
Editorial Policies
CONDITIONS OF ACCEPTANCE
Back to Top
Funding and Conflict of Interest
Authors. Upon submission of the revised manuscript, each author will be asked to disclose all affiliations, funding sources, and financial or management relationships related to the reported research, including those that could be perceived as potential sources of bias. Patents (whether applications or awards to the authors or home institutions) related to the work should also be declared. The editors will decide whether this information will be included in the published manuscript as competing interests. The conflict of interest policy for authors can be viewed here [PDF].
Reviewers. Reviewers form the cornerstone of the peer-review process, and their evaluations ensure the quality of published research. Therefore, the editors seek reviewers for Science Translational Medicine who do not have conflicts of interest with the authors or reported research in the manuscripts they read. In addition to this precaution, reviewers are required to disclose any previously unreported conflicts with the evaluation of the paper and this information is taken into account by the editors when decisions are made.
Editorial Staff. Editors for Science Translational Medicine are required to fill out a conflict of interest form, which is then evaluated by Science/AAAS management. Editors for Science Translational Medicine may not have any financial or management interest in any biotechnology, pharmaceutical or biomedical or engineering device institution or company.
Advisory Board. The members of the Advisory Board are required to fill out a conflict of interest form, which is then maintained and evaluated by the editorial staff. Advisors who have conflicts with any particular paper are recused from seeing that paper at any stage in the evaluation process. Staff editors, who are required to have no conflicts of interest, make all final decisions on manuscripts.
Back to Top
Data Availability after Publication
After publication, all data necessary to understand, assess, and extend the conclusions of the manuscript must be available to any reader of Science Translational Medicine. These data must be in the body of the paper, in the Supplementary Material, or archived in an approved database (with accession number in the acknowledgements) (see section below on data deposition). Exceptions must be discussed with an editor.
We recognize that discipline-specific conventions or special circumstances may occasionally apply, and we will consider these in negotiating compliance with requests. Any concerns about your ability to meet Science Translational Medicine's requirements must be disclosed and discussed with an editor. For further information about accessibility of data and materials, see the following resources.
Cech, T. R. (2003), Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences.
American Psychological Association, Responsible Conduct of Research: Data Sharing and Data Archiving.
National Science Foundation Policy on Data Sharing [PDF].
Back to Top
Data Deposition
Science Translational Medicine supports the efforts of databases that aggregate published data for the use of the scientific community. Therefore, before publication, large data sets (including microarray data, protein or DNA sequences, and atomic coordinates or electron microscopy maps for macromolecular structures) must be deposited in an approved database and an accession number provided for inclusion in the published paper.
Molecular structure data. Atomic coordinates and structure factor files from x-ray structural studies or an ensemble of atomic coordinates from NMR structural studies must be deposited and released at the time of publication. Three-dimensional maps derived by electron microscopy and coordinate data derived from these maps must also be deposited. Approved databases are the Worldwide Protein Data Bank [through the Research Collaboratory for Structural Bioinformatics, Macromolecular Structure Database (MSD EMBL-EBI), or Protein Data Bank Japan], BioMag Res Bank, and Electron Microscopy Data Bank (MSD-EBI), and for synthetic molecules, the Cambridge Crystallographic Data Centre.
DNA and protein sequences. Approved databases are GenBank or other members of the InternationalNucleotide Sequence Database Collaboration (EMBL or DDBJ) and SWISS-PROT.
Microarray data. Data should be presented in MIAME-compliant standard format. Approved databases are Gene Expression Omnibus and ArrayExpress.
Protein and molecular interaction data (optional).
Large data sets with no appropriate approved repository must be housed as Supplementary Material at Science Translational Medicine, or when this is not possible, on the author's web site, provided a copy of the data is held in escrow at ScienceTranslational Medicine to ensure availability to readers. Science Translational Medicine follows Science's policies for Supplementary Material; for more information about what can be accommodated and how to prepare these files, see the Science guidelines.
Back to Top
Materials Sharing
After publication, all reasonable requests for materials must be fulfilled. A charge for time and materials involved in the transfer may be made. Science Translational Medicine must be informed of any restrictions on sharing of materials (including Material Transfer Agreements) applying to materials used or created in the reported research. Any such restrictions should be indicated in the cover letter at the time of submission, and each individual author will be asked to reaffirm this when he or she submits the final version of the manuscript. The nature of the restrictions should be noted in the paper. Unreasonable restrictions may preclude publication.
Back to Top
Copyright and License to Publish
Authors retain copyright but agree to grant to Science Translational Medicine an exclusive license to publish the paper in print and online.
Back to Top
Access Policies and Deposition of Papers into Public Archives
After publication, authors may post the accepted version of the paper on the author's personal Web site. In addition, one author is provided a "referrer" link, which can be posted on a personal or institutional Web page and through which users can freely access the published paper on Science Translational Medicine's Web site.
For research papers created under grants for which the authors are required by their funding agencies to make their research results publicly available (for example, from NIH, Howard Hughes Medical Institute, or Wellcome Trust), Science Translational Medicine allows posting of the accepted version of the paper to the funding body's archive or designated repository (such as PubMed Central) six months after publication, provided that a link to the final version of the paper published in Science Translational Medicine is included. (Details can be found here.)
Like all original research papers published in Science journals, original research papers in Science Translational Medicine are freely accessible with registration to any reader on Science Translational Medicine's Web site 12 months after publication.
Authors from institutions that require deposition of their published papers into a publicly accessible institutional archive (for example, Harvard University and MIT ) must obtain a waiver from their institution to publish with Science Translational Medicine.
Back to Top
Figure Processing Fees
To help offset the costs of processing figures for publication, authors of original research papers are asked to pay $300 per figure published in the main paper. The fee is the same for color or black and white figures. There is no charge for figures in Supplementary Material.
Back to Top
Embargo Policy
Submitted and accepted papers will remain privileged documents and will not be released to the press or the public before publication. Questions should be referred to the AAAS Office of Public Programs (202-326-6440). (For more information, please see the embargo entry in the Science Contributors FAQ.)
Back to Top
Detailed Instructions for Individual Manuscript Types
The detailed instructions for each manuscript type outline the format and style requirements for each type of article published in Science Translational Medicine. These instructions also include directions for preparation of text and figures, as well as required file formats, electronic submission instructions and a submission checklist. Each set of instructions is also available as a pdf.
Information about and instructions for preparation of:
New Research Articles
Revised Research Articles
Perspectives
Commentaries
Reviews
Editorial Board
Chief Scientific Advisor:
Elias Zerhouni, M.D.
Senior Fellow, Global Health Program
Bill & Melinda Gates Foundation
Former Director
U.S. National Institutes of Health
Scientific Advisory Board:
Editor-in-Chief, Science:
Bruce Alberts, Ph.D.
Executive Editor, Science:
Monica M. Bradford
Editorial Staff
Editor: Katrina L. Kelner, Ph.D.
Managing Editor: Orla M. Smith, Ph.D.
Senior Editor: Kelly LaMarco, Ph.D.
Associate Editors: Angela Colmone, Ph.D., Heather McDonald, Ph.D.
Consulting Editor: Marc Lavine, Ph.D.
Online Editor, Science: Stewart Wills
Web Content Developer: Martyn Green
Editorial Coordinators: Jill Porco, Anita Saxena
| 
